Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Condition: Gastric, or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU; Drug: Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU Sponsor: BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Chemotherapy | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Xeloda